The debt conversion is a transformative balance-sheet event that removes insolvency risk for a clinical-stage biotech, but the massive dilution (~52%) will pressure the stock near term. Watch for potential overhang when the shares are registered for resale within 180 days. The undrawn $10M facility provides additional runway. Monitor upcoming clinical catalysts for belapectin (MASH cirrhosis) as the primary value driver.
Price Chart
Executive Summary
Galectin Therapeutics (GALT) announced that Chairman Richard Uihlein converted $105.8 million in outstanding convertible debt (principal plus accrued interest) into 34.4 million shares of common stock at a blended ~$3.07/share, eliminating all debt under five credit facilities. The transaction massively strengthens the balance sheet by removing the debt burden but dilutes existing shareholders by approximately 51.7%, while increasing Uihlein's voting power to ~44.3% (actual) or ~49.3% (including warrants). One undrawn $10 million facility remains available.
Key Financial Metrics
Key Facts
- Eliminated $105.8 million in total debt ($91.0M principal + $14.8M accrued interest)
- Issued 34,376,167 shares to Chairman Richard Uihlein upon conversion
- Blended average conversion price of approximately $3.07 per share
- Post-conversion shares outstanding: ~100,849,644 common + 197,500 Series A preferred
- Uihlein's beneficial ownership: ~44.3% voting power actual, ~49.3% including warrants
- One $10M credit facility (December 2025) remains undrawn and available
- Shares unregistered; company obligated to register resale within 180 days
Financial Impact
Debt elimination of $105.8M removes interest burden and default risk; dilution of ~51.7% to existing shareholders (34.4M new shares on ~66.5M pre-conversion base)
Risk Factors
- Massive dilution of ~51.7% to existing shareholders
- Concentration of voting power with Chairman Uihlein (~44-49%)
- Potential share overhang when registration becomes effective within 180 days
- Clinical-stage company with no approved products; belapectin trial risk remains
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001140361-26-031058 |
| Document: ef20079045_ex99-1.htm | 0001140361-26-031058 |
| Document: 0001140361-26-031058-index-headers.html | 0001140361-26-031058 |
| Document: 0001140361-26-031058-index.html | 0001140361-26-031058 |
| Document: 0001140361-26-031058.txt | 0001140361-26-031058 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 13, 2026 13d ago | DEFA14A | $3.69 | awaiting T+20 | — | $3.19 (−13.55%) |
Oct 13, 2026 13d ago | DEF 14A | $3.69 | awaiting T+20 | — | $3.19 (+13.55%) |
Oct 6, 2026 20d ago | Press Release | $3.76 | awaiting T+20 | — | $3.19 (−15.16%) |
Aug 14, 2026 10w ago | Press Release | $3.44 $3.84 | ▲ +11.63% | ▲ +13.62% | $3.19 (−7.27%) |
Aug 14, 2026 10w ago | 8-K | $3.44 $3.84 | ▲ +11.63% | ▲ +13.62% | $3.19 (−7.27%) |
Aug 4, 2026 11w ago | 8-K | $2.99 $4.17 | ▲ +39.46% | ▲ +40.70% | $3.19 (+6.69%) |
Jun 30, 2026 16w ago | Insider Cluster | $4.33 $3.49 | ▼ −19.40% | ▼ −17.21% | $3.19 (−26.33%) |
May 15, 2026 23w ago | Press Release | $2.17 $2.62 | ▲ +20.74% | ▲ +18.62% | $3.19 (+47.00%) |
May 15, 2026 23w ago | 8-K | $2.17 $2.62 | ▲ +20.74% | ▲ +18.62% | $3.19 (+47.00%) |
Apr 13, 2026 28w ago | EFFECT | $2.35 $2.21 | ▼ −5.96% | ▼ −13.69% | $3.19 (+35.74%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers